Diffuse coronary artery disease is a subtype of coronary artery disease (CAD) in which larger sections of coronary arteries have a high plaque buildup. It is less common than focal CAD and can be more ...
Modeyso is the first FDA-approved systemic therapy for H3 K27M-mutant diffuse midline glioma, targeting both adult and pediatric patients. Clinical trials demonstrated a 22% overall response rate with ...
In the article that accompanies this editorial, Bartlett et al 11 present the results of ECHELON-3, a phase III trial comparing brentuximab vedotin + lenalidomide + rituximab (BV + Len + R) with ...
It is, I believe, generally recognized that collaboration among funders is important, because none of us has the resources to make serious inroads on big problems by ourselves. Yet despite widespread ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results